Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 26, Issue , 2020, Pages

  Nikravesh, Niusha ^a   Borchard, Gerrit ^b   Hofmann, Heinrich ^c   Philipp, Erik ^d   Flühmann, Beat ^d   Wick, Peter ^a  

^a SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c EPFL   (Switzerland)

^d Vifor (International) Inc   (Switzerland)

Author keywords

Colloidal nanoparticles; Critical quality attribute; Iron deficiency; Iron carbohydrate complex; Nanomedicine; Physicochemical characterization

Indexed keywords

CARBOHYDRATES; DIGITAL STORAGE; MEDICAL NANOTECHNOLOGY;

BIOLOGICAL ASSESSMENT; COLLOIDAL NANOPARTICLES; CORE SHELL STRUCTURE; CRITICAL QUALITY; GASTROINTESTINAL TRACT; IRON DEFICIENCY; MANUFACTURING PROCESS; PHYSICO-CHEMICAL CHARACTERIZATION;

IRON COMPOUNDS;

CARBOHYDRATE; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERUMOXYTOL; IRON COMPLEX; IRON ISOMALTOSE; IRON NANOPARTICLE; IRON POLYMALTOSE; IRON SACCHARATE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; IRON; IRON DERIVATIVE; NANOPARTICLE;

BACTERIAL GROWTH; CLINICAL OUTCOME; COLLOID; DILUTION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STORAGE; LIGHT; MOISTURE; MOLECULAR WEIGHT; NANOMEDICINE; PARTICLE SIZE; REVIEW; STORAGE TEMPERATURE; SURFACE CHARGE; SUSPENSION; TIME; VISCOSITY; CHEMISTRY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; METABOLISM; PATHOLOGY;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; CARBOHYDRATES; HUMANS; IRON; IRON COMPOUNDS; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE;

EID: 85082804076     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2020.102178     Document Type: Review

References (102)

1. Ling, D., Hyeon, T., Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 9:9‐10 (2013), 1450–1466.
2. Hauser, A.K., Mathias, R., Anderson, K.W., Hilt, J.Z., The effects of synthesis method on the physical and chemical properties of dextran coated iron oxide nanoparticles. Mater. Chem. Phys. 160 (2015), 177–186.
3. Hafner, A., Lovrić, J., Lakoš, G.P., Pepić, I., Nanotherapeutics in the EU: an overview on current state and future directions. Int. J. Nanomedicine, 9, 2014, 1005.
4. Stark, W.J., Nanoparticles in biological systems. Angew. Chemie Int. Ed. 50:6 (2011), 1242–1258.
5. Riehemann, K., Schneider, S.W., Luger, T.A., Godin, B., Ferrari, M., Fuchs, H., Nanomedicine—challenge and perspectives. Angew. Chemie Int. Ed. 48:5 (2009), 872–897.
6. Fendler, J.H., Colloid chemical approach to nanotechnology. Korean J. Chem. Eng. 18:1 (2001), 1–13.
7. Weissig, V., Pettinger, T.K., Murdock, N., Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomedicine, 9, 2014, 4357.
8. Cançado, R.D., Muñoz, M., Intravenous iron therapy: how far have we come?. Rev. Bras. Hematol. Hemoter. 33:6 (2011), 461–469.
9. S. Mühlebach and B. Flühmann, “Iron carbohydrate complexes: characteristics and regulatory challenges,” in Non-Biological Complex Drugs, Springer, 2015, pp. 149–170.
10. Verhoef, J.J.F., et al. Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation. Biomaterials 119 (2017), 68–77.
11. Grzywacz, A., Lubas, A., Fiedor, P., Fiedor, M., Niemczyk, S., Safety and efficacy of intravenous administration of iron preparations. Acta Pol. Pharm. 74:1 (2017), 13–24.
12. Silverstein, S.B., Rodgers, G.M., Parenteral iron therapy options. Am. J. Hematol. 76:1 (2004), 74–78.
13. J. R. Connor, X. Zhang, A. M. Nixon, B. Webb, and J. R. Perno, “Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations,” PLoS One, vol. 10, no. 5, p. e0125272, 2015.
14. Eduardo Toblli, J., Cao, G., Oliveri, L., Angerosa, M., Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm. Allergy-Drug Targets (Formerly Curr. Drug Targets-Inflammation Allergy) 11:1 (2012), 66–78.
15. Geisser, P., Burckhardt, S., The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:1 (2011), 12–33.
16. Powell, J.J., et al. A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity. Nanomedicine Nanotechnology, Biol. Med. 10:7 (2014), 1529–1538.
17. Friedrisch, J.R., Cançado, R.D., Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Rev. Bras. Hematol. Hemoter. 37:6 (2015), 400–405.
18. H. Saito, “Metabolism of iron stores,” Nagoya J. Med. Sci., vol. 76, no. 3–4, p. 235, 2014.
19. D. Sun et al., “Comparative evaluation of US brand and generic intravenous sodium ferric gluconate complex in sucrose injection: physicochemical characterization,” Nanomaterials, vol. 8, no. 1, p. 25, 2018.
20. M. Koralewski, M. Pochylski, and J. Gierszewski, “Magnetic properties of ferritin and akaganeite nanoparticles in aqueous suspension,” J. Nanoparticle Res., vol. 15, no. 9, p. 1902, 2013.
21. García-Fernández, J., et al. The fate of iron nanoparticles used for treatment of iron deficiency in blood using mass-spectrometry based strategies. Microchim. Acta 184:10 (2017), 3673–3680.
22. Auerbach, M., Ballard, H., Clinical use of intravenous iron: administration, efficacy, and safety. ASH Educ. Progr. B. 2010:1 (2010), 338–347.
23. Neiser, S., et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals 28:4 (2015), 615–635.
24. Wu, Y., et al. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy. Int. J. Pharm. 505:1–2 (2016), 167–174.
25. V. Ayala, A. P. Herrera, M. Latorre-Esteves, M. Torres-Lugo, and C. Rinaldi, “Effect of surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron oxide nanoparticles,” J. Nanoparticle Res., vol. 15, no. 8, p. 1874, 2013.
26. Danielson, B.G., Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol. 15:suppl 2 (2004), S93–S98.
27. Kudasheva, D.S., Lai, J., Ulman, A., Cowman, M.K., Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J. Inorg. Biochem. 98:11 (2004), 1757–1769.
28. Van Wyck, D., Anderson, J., Johnson, K., Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol. Dial. Transplant. 19:3 (2004), 561–565.
29. Van Wyck, D.B., Labile iron: manifestations and clinical implications. J. Am. Soc. Nephrol. 15:SUPPL. 2 (2004), 107–111.
30. Gupta, A., Pratt, R.D., Crumbliss, A.L., Ferrous iron content of intravenous iron formulations. Biometals 29:3 (2016), 411–415.
31. F. Funk, P. Ryle, C. Canclini, S. Neiser, and P. Geisser, “The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose,” Arzneimittel-Forschung/Drug Res., vol. 60, no. 6, p. 345, 2010.
32. Borchard, G., Flühmann, B., Mühlebach, S., Nanoparticle iron medicinal products — requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regul. Toxicol. Pharmacol. 64:2 (2012), 324–328.
33. Shah, R.B., Yang, Y., Khan, M.A., Raw, A., Lawrence, X.Y., Faustino, P.J., Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: Iron sucrose. Int. J. Pharm. 464:1–2 (2014), 46–52.
34. “Guideline for elemental impurities Q3D.” [Online]. Available: https://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
35. John, B., Herb Pa, R., Iron preparations and methods of makeng and administering the same. 1979.
36. J. T. Mahajan Purbita Chakraborty, “Effect of variation of process parameters on stability of colloidal metal-complexes,” Der Pharma Chem., vol. 9, no. 9, pp. 19–23, 2017.
37. Toblli, J.E., Cao, G., Angerosa, M., Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations. Int. J. Cardiol. 187:1 (2015), 196–197.
38. Pai, A.B., Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation. 2017, Ann. N. Y. Acad. Sci.
39. Zou, P., Tyner, K., Raw, A., Lee, S., Physicochemical characterization of iron carbohydrate colloid drug products. AAPS J. 19:5 (2017), 1359–1376.
40. Seshagiri R. Tata-Venkata, I. L. (US); X. Z. Chicago, I. L. (US); F. G. Gurnee, I. L. (US); M. Wilmette, and L. V. Siddiqui IL (US), “Packaged iron sucrose products,” 2011.
41. S. A. Pillai, D. Chobisa, D. Urimi, and N. Ravindra, “Pharmaceutical glass interactions: a review of possibilities,” J. Pharm. Sci. Res., vol. 8, no. 2, p. 103, 2016.
42. Toblli, J.E., Cao, G., Oliveri, L., Angerosa, M., Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 59:04 (2009), 176–190.
43. Astier, A., et al. How to select a nanosimilar. Ann. N. Y. Acad. Sci. 1407:1 (2017), 50–62.
44. Rottembourg, J., Kadri, A., Leonard, E., Dansaert, A., Lafuma, A., Do two intravenous iron sucrose preparations have the same efficacy?. Nephrol. Dial. Transplant. 26:10 (2011), 3262–3267.
45. Perfetti, G., Aubert, T., Wildeboer, W.J., Meesters, G.M.H., Influence of handling and storage conditions on morphological and mechanical properties of polymer-coated particles: characterization and modeling. Powder Technol. 206:1–2 (2011), 99–111.
46. Baer, D.R., et al. Characterization challenges for nanomaterials. Surf. Interface Anal. 40:3‐4 (2008), 529–537.
47. Izak-Nau, E., et al. Impact of storage conditions and storage time on silver nanoparticles’ physicochemical properties and implications for their biological effects. Rsc Adv. 5:102 (2015), 84172–84185.
48. Jasbi, N.E., Dorranian, D., Effect of aging on the properties of TiO2 nanoparticle. J. Theor. Appl. Phys. 10:3 (2016), 157–161.
49. Karaagac, O., Kockar, H., Tanrisever, T., Properties of iron oxide nanoparticles synthesized at different temperatures. J. Supercond. Nov. Magn. 24:1–2 (2011), 675–678.
50. Sharma, H., Mishra, P.K., Talegaonkar, S., Vaidya, B., Metal nanoparticles: a theranostic nanotool against cancer. Drug Discov. Today 20:9 (2015), 1143–1151.
51. Parkkinen, J., von Bonsdorff, L., Peltonen, S., Grönhagen‐Riska, C., Rosenlöf, K., Catalytically active iron and bacterial growth in serum of haemodialysis patients after iv iron-saccharate administration. Nephrol. Dial. Transplant. 15:11 (2000), 1827–1834.
52. Baribeault, D., Short-term stability of a new generic sodium ferric gluconate in complex with sucrose. Curr. Med. Res. Opin. 27:12 (2011), 2241–2243.
53. Yang, Y., Shah, R.B., Faustino, P.J., Raw, A., Yu, L.X., Khan, M.A., Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate. J. Pharm. Sci. 99:1 (2010), 142–153.
54. Kumpf, V.J., Holland, E.G., Parenteral iron dextran therapy. DICP 24:2 (1990), 162–166.
55. Patel, R.P., Wanandy, T., Loring, S., Johns, C., Hutchinson, J., Shastri, M., Stability of diluted iron polymaltose in PVC infusion bags. J. Pharm. Pract. Res. 43:2 (2013), 112–116.
56. Philipp, E., Braitsch, M., Bichsel, T., Mühlebach, S., Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability. Eur J Hosp Pharm 23:1 (2016), 22–27.
57. Zaloga, J., et al. Different storage conditions influence biocompatibility and physicochemical properties of iron oxide nanoparticles. Int. J. Mol. Sci. 16:5 (2015), 9368–9384.
58. Wabler, M., et al. Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content. Int. J. Hyperth. 30:3 (2014), 192–200.
59. Locatelli, F., Canaud, B., Eckardt, K., Stenvinkel, P., Wanner, C., Zoccali, C., Oxidative stress in end‐stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant. 18:7 (2003), 1272–1280.
60. E. Suvikas-Peltonen, S. Hakoinen, E. Celikkayalar, R. Laaksonen, and M. Airaksinen, “Incorrect aseptic techniques in medicine preparation and recommendations for safer practices: a systematic review,” Eur J Hosp Pharm, p. ejhpharm-2016-001015, 2016.
61. Mikhail, A., Shrivastava, R., Richardson, D., Renal association clinical practice guideline on anaemia of chronic kidney disease. Nephron Clin. Pract. 118:Suppl. 1 (2011), c101–c124.
62. “EU clinical trials register.” European Medicines Agency Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands.
63. Koch, T.A., Myers, J., Goodnough, L.T., Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia, vol., 2015, 2015.
64. Kalra, P.A., Bhandari, S., Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int. J. Nephrol. Renovasc. Dis., 9, 2016, 53.
65. S. Bhandari, D. Pereira, H. Chappell, and H. Drakesmith, “Intravenous irons: from basic science to clinical practice,” Pharmaceuticals, vol. 11, no. 3, p. 82, 2018.
66. Blazevic, A., Hunze, J., Boots, J.M., Severe hypophosphataemia after intravenous iron administration. Neth J Med 72:1 (2014), 49–53.
67. emc, “Venofer (iron sucrose).” [Online]. Available: https://www.medicines.org.uk/emc/product/5911/smpc.
68. emc, “Ferinject (ferric carboxymaltose).” [Online]. Available: https://www.medicines.org.uk/emc/product/5910/smpc.
69. emc, “Iron dextran.” [Online]. Available: https://www.medicines.org.uk/emc/product/48/smpc.
70. Bager, P., Hvas, C.L., Dahlerup, J.F., Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br. J. Clin. Pharmacol. 83:5 (2017), 1118–1125.
71. J. G. A. Rottembourg, M. Diaconita, and A. Kadri, “The complete study of the switch from iron-sucrose originator to iron-sucrose similar and vice versa in hemodialysis patients,” J Kidney, vol. 2, no. 1, p. 110, 2016.
72. M. L. Agüera et al., “Efficiency of original versus generic intravenous iron formulations in patients on haemodialysis,” PLoS One, vol. 10, no. 8, p. e0135967, 2015.
73. Auerbach, M., Macdougall, I., The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial. Int. 21 (2017), S83–S92.
74. B. S. Barot, P. B. Parejiya, P. K. Shelat, G. B. Shah, D. M. Mehta, and T. V Pathak, “Physicochemical and toxicological characterization of sucrose-bound polynuclear iron oxyhydroxide formulations,” J. Pharm. Investig., vol. 45, no. 1, pp. 35–49, 2015.
75. Fütterer, S., Andrusenko, I., Kolb, U., Hofmeister, W., Langguth, P., Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J. Pharm. Biomed. Anal. 86 (2013), 151–160.
76. Somsook, E., et al. Interactions between iron (III) and sucrose, dextran, or starch in complexes. Carbohydr. Polym. 61:3 (2005), 281–287.
77. Funk, F., Long, G.J., Hautot, D., Büchi, R., Christl, I., Weidler, P.G., Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the β-FeOOH or ferrihydrite structure. Hyperfine Interact. 136:1–2 (2001), 73–95.
78. Balakrishnan, V.S., et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur. J. Clin. Invest. 39:6 (2009), 489–496.
79. Morrison, I.D., Ross, S., Colloidal dispersions: suspensions, emulsions, and foams. Wiley-Interscience New York, 2002.
80. Di Francesco, T., Philipp, E., Borchard, G., Iron sucrose: assessing the similarity between the originator drug and its intended copies. Ann. N. Y. Acad. Sci. 1407:1 (2017), 63–74.
81. Bullivant, J.P., Zhao, S., Willenberg, B.J., Kozissnik, B., Batich, C.D., Dobson, J., Materials characterization of feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia. Int. J. Mol. Sci. 14:9 (2013), 17501–17510.
82. H. J. Manley and D. W. Grabe, “Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitro study,” BMC Nephrol., vol. 5, no. 1, p. 1, 2004.
83. Martin-Malo, A., et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol. Dial. Transplant. 27:6 (2011), 2465–2471.
84. Brȩborowicz, M., Polubinska, A., Tam, P., Wu, G., Brȩborowicz, A., Effect of iron sucrose on human peritoneal mesothelial cells. Eur. J. Clin. Invest. 33:12 (2003), 1038–1044.
85. Shah, A., Mankus, C.I., Vermilya, A.M., Soheilian, F., Clogston, J.D., Dobrovolskaia, M.A., Feraheme® suppresses immune function of human T lymphocytes through mitochondrial damage and mitoROS production. Toxicol. Appl. Pharmacol. 350 (2018), 52–63.
86. Hempel, J.C., et al. Distinct in vitro complement activation by various intravenous iron preparations. Am. J. Nephrol. 45:1 (2017), 49–59.
87. Meier, T., Schropp, P., Pater, C., Leoni, A.-L., Elford, P., Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Arzneimittelforschung 61:02 (2011), 112–119.
88. Liakopoulos, V., Roumeliotis, S., Gorny, X., Dounousi, E., Mertens, P.R., Oxidative stress in hemodialysis patients: a review of the literature. Oxid. Med. Cell. Longev, vol. 2017, 2017.
89. Praschberger, M., et al. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity. Biometals 28:1 (2015), 35–50.
90. Legssyer, R., Geisser, P., McArdle, H., Crichton, R.R., Ward, R.J., Comparison of injectable iron complexes in their ability to iron load tissues and to induce oxidative stress. Biometals 16:3 (2003), 425–433.
91. Kohgo, Y., Ikuta, K., Ohtake, T., Torimoto, Y., Kato, J., Body iron metabolism and pathophysiology of iron overload. Int. J. Hematol. 88:1 (2008), 7–15.
92. Tinkle, S., et al. Nanomedicines: addressing the scientific and regulatory gap. Ann. N. Y. Acad. Sci. 1313:1 (2014), 35–56.
93. Ghoti, H., et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur. J. Haematol. 89:1 (2012), 87–93.
94. Naoum, F.A., Iron deficiency in cancer patients. Rev. Bras. Hematol. Hemoter. 38:4 (2016), 325–330.
95. Del Vecchio, L., Longhi, S., Locatelli, F., Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin. Kidney J. 9:2 (2016), 260–267.
96. Walters, B.A.J., Van Wyck, D.B., Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrol. Dial. Transplant. 20:7 (2005), 1438–1442.
97. B. V Stefánsson, B. Haraldsson, and U. Nilsson, “Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran,” Nephron Clin. Pract., vol. 118, no. 3, pp. c249–c256, 2011.
98. Macdougall, I.C., Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. Clin. Kidney J. vol. 10:suppl_1 (2017), i16–i24.
99. Macdougall, I.C., et al. Iron management in chronic kidney disease: conclusions from a ‘Kidney Disease: Improving Global Outcomes’(KDIGO) Controversies Conference. Kidney Int. 89:1 (2016), 28–39.
100. T. Avni, A. Bieber, A. Grossman, H. Green, L. Leibovici, and A. Gafter-Gvili, “The safety of intravenous iron preparations: systematic review and meta-analysis,” in Mayo Clinic Proceedings, 2015, vol. 90, no. 1, pp. 12–23.
101. Zager, R.A., Johnson, A.C.M., Hanson, S.Y., Wasse, H., Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am. J. kidney Dis. 40:1 (2002), 90–103.
102. P. Geisser and A. Müller, “Pharmacokinetics of iron salts and ferric hydroxide-carbohydrate complexes,” Arzneimittelforschung, vol. 37, no. 1A, pp. 100–104, 1987.